KRAS and colorectal carcinoma: The accumulation of these gene mutations eventually drives CRC carcinogenesis, hence this model is alternatively referred to as “adenoma‐carcinoma sequence model.”15 Mutations in several pivotal genes in the model, such as KRAS, TP53, and BRAF, demonstrate prognostic and predictive value and are routinely employed for therapeutic prediction in clinical practice.16